Rx Patent Cases For Five Drugs Could Lead To Delayed Generics - FDA
Executive Summary
Five ongoing patent challenge cases have the potential to delay generic availability, FDA's Office of Generic Drugs Acting Director Gary Buehler told a House Commerce/Health Subcommittee hearing June 13.
You may also be interested in...
FDA Generic Biologic Decision Could Be Prompted With Petition – Barr
Generic drug manufacturers may need to push FDA to make a decision on a pathway for approving generic biologic products by submitting citizen petitions, Barr Research VP-New Drug Development Robert Bill, PhD, told a Center for Business Intelligence conference Nov. 29 in Washington, D.C
FDA Generic Biologic Decision Could Be Prompted With Petition – Barr
Generic drug manufacturers may need to push FDA to make a decision on a pathway for approving generic biologic products by submitting citizen petitions, Barr Research VP-New Drug Development Robert Bill, PhD, told a Center for Business Intelligence conference Nov. 29 in Washington, D.C
BIO Generic Biologics Position: All Products Need "Rigorous" Clinical Trials
The Biotechnology Industry Organization position statement on generic biologics is firmly against any shortcuts to market for follow-on products.